Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1990 May;85(5):1507–1515. doi: 10.1172/JCI114597

Pathogenesis of an experimental model of Goodpasture's hemorrhagic pneumonitis.

T H Queluz 1, I Pawlowski 1, M J Brunda 1, J R Brentjens 1, A O Vladutiu 1, G Andres 1
PMCID: PMC296598  PMID: 2185275

Abstract

The mechanisms that allow circulating basement membrane antibodies (Ab) to interact with the alveolar basement membrane (ABM) inducing Goodpasture's hemorrhagic pneumonitis are unknown. In laboratory animals the ABM is inaccessible to phlogogenic amounts of ABM Ab unless the permeability of the unfenestrated alveolar endothelium is increased. This study was designed to test the hypothesis that in the mouse polypeptide mediators, generated by activated lymphoid cells or cells infected by viruses, contribute to the pathogenesis of passive Goodpasture's hemorrhagic pneumonitis. In naive mice that received rabbit ABM Ab, these bound to the glomerular basement membrane but not to the ABM and their lungs were normal. In the lungs of mice injected with human recombinant IL-2 and IFN-alpha specific binding of ABM IgG, C3, and fibrinogen to the ABM, diffuse and severe erythrocyte extravasation, and accumulation of mononuclear and polymorphonuclear leukocytes were constantly observed. ABM Ab and IL-2 or ABM Ab and IFN-alpha did not produce comparable effects. Mice injected only with IL-2 and IFN-alpha had enlarged, edematous lungs without pulmonary hemorrhages. The results show that the synergism of IL-2 and IFN-alpha convert the lung into a preferential target for AMB Ab, suggesting that cytokines may have a role in the pathogenesis of human Goodpasture's pneumonitis.

Full text

PDF
1507

Images in this article

1510Image
on p.1510
1510Image
on p.1510
1510Image
on p.1510
1511Image
on p.1511
1512Image
on p.1512
1512Image
on p.1512
1512Image
on p.1512
1513Image
on p.1513
1513Image
on p.1513

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andres G. A., Accinni L., Beiser S. M., Christian C. L., Cinotti G. A., Erlanger B. F., Hsu K. C., Seegal B. C. Localization of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis. J Clin Invest. 1970 Nov;49(11):2106–2118. doi: 10.1172/JCI106428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aronson F. R., Libby P., Brandon E. P., Janicka M. W., Mier J. W. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol. 1988 Jul 1;141(1):158–163. [PubMed] [Google Scholar]
  3. Avasthi P. S., Avasthi P., Tokuda S., Anderson R. E., Williams R. C., Jr Experimental glomerulonephritis in the mouse. I. The model. Clin Exp Immunol. 1971 Nov;9(5):667–676. [PMC free article] [PubMed] [Google Scholar]
  4. Bevilacqua M. P., Pober J. S., Majeau G. R., Cotran R. S., Gimbrone M. A., Jr Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984 Aug 1;160(2):618–623. doi: 10.1084/jem.160.2.618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bevilacqua M. P., Pober J. S., Mendrick D. L., Cotran R. S., Gimbrone M. A., Jr Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9238–9242. doi: 10.1073/pnas.84.24.9238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brunda M. J., Rosenbaum D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res. 1984 Feb;44(2):597–601. [PubMed] [Google Scholar]
  7. Brunda M. J., Tarnowski D., Davatelis V. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer. 1986 May 15;37(5):787–793. doi: 10.1002/ijc.2910370522. [DOI] [PubMed] [Google Scholar]
  8. Clayman M. D., Michaud L., Neilson E. G. Murine interstitial nephritis. VI. Characterization of the B cell response in anti-tubular basement membrane disease. J Immunol. 1987 Oct 1;139(7):2242–2249. [PubMed] [Google Scholar]
  9. Cybulsky M. I., Colditz I. G., Movat H. Z. The role of interleukin-1 in neutrophil leukocyte emigration induced by endotoxin. Am J Pathol. 1986 Sep;124(3):367–372. [PMC free article] [PubMed] [Google Scholar]
  10. Damle N. K., Doyle L. V., Bender J. R., Bradley E. C. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol. 1987 Mar 15;138(6):1779–1785. [PubMed] [Google Scholar]
  11. Downie G. H., Roholt O. A., Jennings L., Blau M., Brentjens J. R., Andres G. A. Experimental anti-alveolar basement membrane antibody-mediated pneumonitis. II. Role of endothelial damage and repair, induction of autologous phase, and kinetics of antibody deposition in Lewis rats. J Immunol. 1982 Dec;129(6):2647–2652. [PubMed] [Google Scholar]
  12. Ettinghausen S. E., Puri R. K., Rosenberg S. A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst. 1988 Apr 6;80(3):177–188. doi: 10.1093/jnci/80.3.177. [DOI] [PubMed] [Google Scholar]
  13. Ewan P. W., Rees A. J. Pulmonary hemorrhage in Goodpasture's syndrome. N Engl J Med. 1977 Mar 10;296(10):574–575. doi: 10.1056/NEJM197703102961020. [DOI] [PubMed] [Google Scholar]
  14. Gately M. K., Anderson T. D., Hayes T. J. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J Immunol. 1988 Jul 1;141(1):189–200. [PubMed] [Google Scholar]
  15. Gaynor E. R., Vitek L., Sticklin L., Creekmore S. P., Ferraro M. E., Thomas J. X., Jr, Fisher S. G., Fisher R. I. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1988 Dec 15;109(12):953–958. doi: 10.7326/0003-4819-109-12-953. [DOI] [PubMed] [Google Scholar]
  16. Hudson B. G., Wieslander J., Wisdom B. J., Jr, Noelken M. E. Goodpasture syndrome: molecular architecture and function of basement membrane antigen. Lab Invest. 1989 Sep;61(3):256–269. [PubMed] [Google Scholar]
  17. Jennings L., Roholt O. A., Pressman D., Blau M., Andres G. A., Brentjens J. R. Experimental anti-alveolar basement membrane antibody-mediated pneumonitis. I. The role of increased permeability of the alveolar capillary wall induced by oxygen. J Immunol. 1981 Jul;127(1):129–134. [PubMed] [Google Scholar]
  18. Lerner R. A., Dixon F. J. Transfer of ovine experimental allergic glomerulonephritis (EAG) with serum. J Exp Med. 1966 Sep 1;124(3):431–442. doi: 10.1084/jem.124.3.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lerner R. A., Glassock R. J., Dixon F. J. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967 Dec 1;126(6):989–1004. doi: 10.1084/jem.126.6.989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Marlin S. D., Springer T. A. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987 Dec 4;51(5):813–819. doi: 10.1016/0092-8674(87)90104-8. [DOI] [PubMed] [Google Scholar]
  21. McConahey P. J., Dixon F. J. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol. 1966;29(2):185–189. doi: 10.1159/000229699. [DOI] [PubMed] [Google Scholar]
  22. Meezan E., Hjelle J. T., Brendel K., Carlson E. C. A simple, versatile, nondisruptive method for the isolation of morphologically and chemically pure basement membranes from several tissues. Life Sci. 1975 Dec 1;17(11):1721–1732. doi: 10.1016/0024-3205(75)90119-8. [DOI] [PubMed] [Google Scholar]
  23. Moser R., Schleiffenbaum B., Groscurth P., Fehr J. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest. 1989 Feb;83(2):444–455. doi: 10.1172/JCI113903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ognibene F. P., Rosenberg S. A., Lotze M., Skibber J., Parker M. M., Shelhamer J. H., Parrillo J. E. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest. 1988 Oct;94(4):750–754. doi: 10.1378/chest.94.4.750. [DOI] [PubMed] [Google Scholar]
  25. PIRANI C. L., POLLAK V. E., SCHWARTZ F. D. THE REPRODUCIBILITY OF SEMIQUANTITATIVE ANALYSES OF RENAL HISTOLOGY. Nephron. 1964;1:230–237. doi: 10.1159/000179336. [DOI] [PubMed] [Google Scholar]
  26. PRESSMAN D., DAY E. D., BLAU M. The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res. 1957 Oct;17(9):845–850. [PubMed] [Google Scholar]
  27. Perez G. O., Bjornsson S., Ross A. H., Aamato J., Rothfield N. A mini-epidemic of Goodpasture's syndrome clinical and immunological studies. Nephron. 1974;13(2):161–173. doi: 10.1159/000180389. [DOI] [PubMed] [Google Scholar]
  28. Pober J. S., Bevilacqua M. P., Mendrick D. L., Lapierre L. A., Fiers W., Gimbrone M. A., Jr Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol. 1986 Mar 1;136(5):1680–1687. [PubMed] [Google Scholar]
  29. Puri R. K., Rosenberg S. A. Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice. Cancer Immunol Immunother. 1989;28(4):267–274. doi: 10.1007/BF00205236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rees A. J., Lockwood C. M., Peters D. K. Enhanced allergic tissue injury in Goodpasture's syndrome by intercurrent bacterial infection. Br Med J. 1977 Sep 17;2(6089):723–726. doi: 10.1136/bmj.2.6089.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rehberg E., Kelder B., Hoal E. G., Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem. 1982 Oct 10;257(19):11497–11502. [PubMed] [Google Scholar]
  32. Roder J. C., Lohmann-Matthes M. L., Domzig W., Wigzell H. The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol. 1979 Nov;123(5):2174–2181. [PubMed] [Google Scholar]
  33. Roder J. C. The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol. 1979 Nov;123(5):2168–2173. [PubMed] [Google Scholar]
  34. Rosenberg S. A., Grimm E. A., McGrogan M., Doyle M., Kawasaki E., Koths K., Mark D. F. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  35. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  36. Rosenberg S. A., Mulé J. J., Spiess P. J., Reichert C. M., Schwarz S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985 May 1;161(5):1169–1188. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Rosenstein M., Ettinghausen S. E., Rosenberg S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735–1742. [PubMed] [Google Scholar]
  38. Saxena R. K., Saxena Q. B., Adler W. H. Defective T-cell response in beige mutant mice. Nature. 1982 Jan 21;295(5846):240–241. doi: 10.1038/295240a0. [DOI] [PubMed] [Google Scholar]
  39. Steblay R. W., Rudofsky U. H. Experimental autoimmune antiglomerular basement membrane antibody-induced glomerulonephritis. I. The effects of injecting sheep with human, homologous or autologous lung basement membranes and complete Freund's adjuvant. Clin Immunol Immunopathol. 1983 Apr;27(1):65–80. doi: 10.1016/0090-1229(83)90057-0. [DOI] [PubMed] [Google Scholar]
  40. Toy J. L. The interferons. Clin Exp Immunol. 1983 Oct;54(1):1–13. [PMC free article] [PubMed] [Google Scholar]
  41. Trinchieri G., Perussia B. Human natural killer cells: biologic and pathologic aspects. Lab Invest. 1984 May;50(5):489–513. [PubMed] [Google Scholar]
  42. Wilson C. B., Dixon F. J. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973 Feb;3(2):74–89. doi: 10.1038/ki.1973.14. [DOI] [PubMed] [Google Scholar]
  43. Wilson C. B., Dixon F. J. Antigen quantitation in experimental immune complex glomerulonephritis. I. Acute serum sickness. J Immunol. 1970 Aug;105(2):279–290. [PubMed] [Google Scholar]
  44. Wilson C. B., Smith R. C. Goodpasture's syndrome associated with influenza A2 virus infection. Ann Intern Med. 1972 Jan;76(1):91–94. doi: 10.7326/0003-4819-76-1-91. [DOI] [PubMed] [Google Scholar]
  45. Yamamoto T., Wilson C. B. Binding of anti-basement membrane antibody to alveolar basement membrane after intratracheal gasoline instillation in rabbits. Am J Pathol. 1987 Mar;126(3):497–505. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES